Research article Special Issues

Compare with safety and efficacy of entecavir and adefovir dipivoxil combination therapy and tenofovir disoproxil fumarate monotherapy for chronic hepatitis B patient with adefovir-resistant

  • Received: 03 April 2019 Accepted: 24 September 2019 Published: 21 October 2019
  • Objective To compare the 2-year efficacy and safety of combination therapy with entecavir (ETV) and adefovir dipivoxil (ADV) to that of tenofovir disoproxil fumarate (TDF) monotherapy in treatment of patients with adefovir drug-resistant chronic hepatitis B.
    Methods HBeAg-positive CHB patients (n = 100) with adefovir-resistance (rtA181T/V and/or rtN236T) were enrolled. Patients were treated with either ETV 0.5 mg plus ADV 10 mg per day (n = 52) or TDF 300 mg per day (n = 48) for 48 weeks. Tests for liver and kidney function, Serum Phosphorus, HBV serum markers, HBV DNA load and ultrasonography of liver were performed every 3 months. Student's t-test and χ2 test were used to compare the efficacy, side effects in the two groups.
    Results Fifty-two patients in ETV + ADV group and forty-eight patients in TDF group were followed-up for 96 weeks. HBV DNA undetectable rate were 76.9% versus 81.3% (P = 0.631) at week 48, and 92.3% versus 95.8% (P = 0.679) at week 96 in ETV + ADV combination therapy and TDF monotherapy group respectively. Serum ALT normalized rate were 84.6% versus 87.5% (P = 0.777) at week 48, and 92.3% versus 95.8% (P = 0.679) at week 96 in ETV+ADV combination therapy and TDF monotherapy group respectively. But the level of serum Phosphorus was significantly lower in ETV + ADV combination therapy group compare with TDF monotherapy group (1.13 ±0.15 versus 1.22 ±0.16, P = 0.004) at week 96.
    Conclusion Both ETV + ADV combination therapy and TDF monotherapy provided effective treatments in chronic hepatitis B with adefovir-resistant. However, it was associated with poor serological responses up to week 96. The long term treatment of hepatitis B with ETV (0.5 mg/day) combination of ADV (10 mg/day) can potentially cause hypophosphatemia and renal impairment, so regular monitoring of serum phosphate, serum creatinine and evaluation of eGFR is needed.

    Citation: Ming-Chun Lai, Jiang-Shan Lian, Wen-Jin Zhang, Jun Xu, Lin Zhou, Shu-Sen Zheng. Compare with safety and efficacy of entecavir and adefovir dipivoxil combination therapy and tenofovir disoproxil fumarate monotherapy for chronic hepatitis B patient with adefovir-resistant[J]. Mathematical Biosciences and Engineering, 2020, 17(1): 627-635. doi: 10.3934/mbe.2020032

    Related Papers:

  • Objective To compare the 2-year efficacy and safety of combination therapy with entecavir (ETV) and adefovir dipivoxil (ADV) to that of tenofovir disoproxil fumarate (TDF) monotherapy in treatment of patients with adefovir drug-resistant chronic hepatitis B.
    Methods HBeAg-positive CHB patients (n = 100) with adefovir-resistance (rtA181T/V and/or rtN236T) were enrolled. Patients were treated with either ETV 0.5 mg plus ADV 10 mg per day (n = 52) or TDF 300 mg per day (n = 48) for 48 weeks. Tests for liver and kidney function, Serum Phosphorus, HBV serum markers, HBV DNA load and ultrasonography of liver were performed every 3 months. Student's t-test and χ2 test were used to compare the efficacy, side effects in the two groups.
    Results Fifty-two patients in ETV + ADV group and forty-eight patients in TDF group were followed-up for 96 weeks. HBV DNA undetectable rate were 76.9% versus 81.3% (P = 0.631) at week 48, and 92.3% versus 95.8% (P = 0.679) at week 96 in ETV + ADV combination therapy and TDF monotherapy group respectively. Serum ALT normalized rate were 84.6% versus 87.5% (P = 0.777) at week 48, and 92.3% versus 95.8% (P = 0.679) at week 96 in ETV+ADV combination therapy and TDF monotherapy group respectively. But the level of serum Phosphorus was significantly lower in ETV + ADV combination therapy group compare with TDF monotherapy group (1.13 ±0.15 versus 1.22 ±0.16, P = 0.004) at week 96.
    Conclusion Both ETV + ADV combination therapy and TDF monotherapy provided effective treatments in chronic hepatitis B with adefovir-resistant. However, it was associated with poor serological responses up to week 96. The long term treatment of hepatitis B with ETV (0.5 mg/day) combination of ADV (10 mg/day) can potentially cause hypophosphatemia and renal impairment, so regular monitoring of serum phosphate, serum creatinine and evaluation of eGFR is needed.


    加载中


    [1] J. J. Ott, G. A. Stevens, J. Groeger, et al., Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity, Vaccine, 30 (2012); 2212-2219.
    [2] U. H. Iloeje, H. I. Yang, J. Su, et al., Predicting cirrhosis risk based on the level of circulating hepatitis B viral load, Gastroenterology, 130 (2006), 678-686.
    [3] G. A. Kim, Y. S. Lim, S. Han, et al., High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B, Gut, 67 (2018), 945-952.
    [4] M. Aizawa, A. Tsubota, K. Fujise, et al., Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients, J. Med. Virol., 83 (2011), 953-961.
    [5] R. P. Perrillo, H. W. Hann, E. Schiff, et al., Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance, Hepatol. Int., 5 (2011), 654-663. doi: 10.1007/s12072-010-9228-9
    [6] N. A. Terrault, N. H. Bzowej, K. M. Chang, et al., AASLD guidelines for treatment of chronic hepatitis B, Hepatology, 63 (2016), 261-283.
    [7] C. L. Lai, J. Dienstag, E. Schiff, et al., Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B, Clin. Infect. Dis., 36 (2003), 687-696.
    [8] W. Ke, L. Liu, C. Zhang, et al., Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: A systematic review and meta-analysis, PLoS One, 9 (2014), e98865.
    [9] F. Güzelbulut, A. O. Ovünç, Z. A. Oetinkaya, et al., Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B, Hepatogastroenterology, 59 (2012), 477-480.
    [10] Z. B. Huang, S. S. Zhao, Y. Huang, et al., Comparison of the Efficacy of Lamivudine Plus Adefovir Versus Entecavir in the Treatment of Lamivudine-Resistant Chronic Hepatitis B: A Systematic Review and Meta-Analysis, Clin. Ther., 35 (2013), 1997-2006.
    [11] A. S. Lok, B. J. McMahon, R. S. Brown, et al., Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis, Hepatology, 63 (2016), 284-306.
    [12] W. K. Seto, Y. F. Lam, J. Fung, et al., Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment, J. Gastroenterol. Hepatol., 29 (2014), 1028-1034.
    [13] M. Buti, N. Tsai, J. Petersen, et al., Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection, Dig. Dis. Sci., 60 (2015), 1457-1464.
    [14] Y. F. Liaw, I. S. Sheen, C. M. Lee, et al., Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease, Hepatology, 53 (2011), 62-72. doi: 10.1002/hep.23952
    [15] T. G. Vassiliadis, O. Giouleme, G. Koumerkeridis, et al., Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: A 4-year study, J. Gastroenterol. Hepatol., 25 (2010), 54-60.
    [16] M. Tanaka, F. Suzuki, Y. Seko, et al., Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B, J. Gastroenterol., 49 (2014), 470-480.
    [17] M. L. Chang and Y. F. Liaw, Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management, J. Hepatol., 61 (2014), 1407-1417.
    [18] P. Thurairajah, A. Khanna and D. Mutimer, Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus (J. Viral. Hepat. 2010 Feb 1;17(2):123-9), J. Viral. Hepat., 18 (2011), 810-820.
    [19] Y. J. Kim, H. C. Cho, D. H. Sinn, et al., Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients, J. Gastroenterol. Hepatol., 27 (2012), 306-312.
  • Reader Comments
  • © 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(5096) PDF downloads(632) Cited by(1)

Article outline

Figures and Tables

Figures(1)  /  Tables(2)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog